Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,200 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT06719024RecruitingPhase 2/Phase 3
Ruxolitinib cream for vitiligo on face and neck
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
Hong KongAges 18–85 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT07589543RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Ovarian Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight ovarian cancer that has returned or stopped responding to standard treatments. The therapy uses cells from your own body that have been modified in the lab to recognize and attack cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07587125RecruitingPhase 1
CAR-T Cell Therapy for Progressive Multiple Sclerosis
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
Xi'an, ShaanxiAges 18–75 - NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT07580183Recruiting
Memory and Brain Function in Epilepsy Surgery
This study examines how the brain recognizes spatial scenes (like rooms or landscapes) in people with epilepsy who may have surgery. Researchers want to understand memory patterns before and after surgery to help predict outcomes.
Sacramento, CaliforniaAges 18–55 - NCT06725966Recruiting
Personalized treatment for persistent BPPV
This trial tests a new way to treat a common inner ear condition called BPPV that hasn't improved with standard head maneuvers. It aims to help people whose dizziness keeps coming back.
Santiago de Compostela, A CoruñaAges 18–100 - NCT06725524RecruitingPhase 1
New drug for B-cell lymphoma that returned after treatment
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
ShanghaiAges 18–70 - NCT07572006RecruitingPhase 1
Study of JNJ-95804306 for blood cancers that returned or didn't respond
This trial tests a new drug called JNJ-95804306 for people with certain blood cancers (like acute myeloid leukemia, myelodysplastic syndromes, or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The goal is to see if the drug is safe and if it can help.
Indianapolis, IndianaAges 18 years+ - NCT07570823RecruitingPhase 3
SCTB35 Plus Chemotherapy for Relapsed Lymphoma
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
BeijingAges 18–80 - NCT07570017RecruitingPhase 1
Rocbrutinib Plus Chemotherapy for Resistant B-Cell Lymphoma
This study tests whether combining a new drug called rocbrutinib with standard chemotherapy (R-GemOx) works better for patients whose diffuse large B-cell lymphoma (a type of blood cancer) has stopped responding to previous treatments. Researchers hope this combination may help patients who have limited options.
Guangzhou, GuangdongAges 18 years+ - NCT05053607Recruiting
Text and Fitbit monitoring during isatuximab treatment
This trial follows people with multiple myeloma who are getting isatuximab through a vein (IV). It tests how well real-world health tracking (text/app messages and Fitbit data) works during treatment, and whether it can help care teams understand your experience.
Houston, TexasAges 18 years+ - NCT05451251RecruitingPhase 1
Deep brain stimulation for severe trigeminal nerve pain
This trial tests whether deep brain stimulation can reduce intense facial pain from trigeminal neuralgia when medicines and prior procedures have not helped. You may be eligible if you’re an adult with a specific MRI finding near the trigeminal nerve pathway.
Sherbrooke, QuebecAges 18 years+ - NCT06730659RecruitingPhase 1
CHT101 for CD70-positive advanced solid tumors
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
TianjinAges 18–70 - NCT06083207RecruitingPhase 1/Phase 2
IBI3003 for multiple myeloma that has returned or not responded
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
Wollongong, New South WalesAges 18 years+ - NCT07562022RecruitingPhase 3
SCTB35 Plus Lenalidomide for Resistant Follicular Lymphoma
This trial tests a new drug called SCTB35 combined with lenalidomide (a known cancer drug) in people whose follicular lymphoma (a type of blood cancer) has stopped responding to or come back after previous treatments. The combination may help shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–80 - NCT07559799Recruiting
Melflufen and Dexamethasone for Relapsed Multiple Myeloma
This study tracks how melflufen (a cancer-fighting drug) combined with dexamethasone works in patients with multiple myeloma that has returned or stopped responding to previous treatments. Researchers will monitor your health and quality of life over time to understand the treatment's real-world effectiveness.
Freiburg im BreisgauAges 18 years+ - NCT06732492RecruitingPhase 1
RD13-02 cell therapy for relapsed CD7+ NK/T lymphoma
This trial uses a new type of immune cell (RD13-02) to treat a rare and aggressive lymphoma that hasn't responded to other treatments. It targets cancer cells that carry a specific marker called CD7.
Wuhan, HubeiAges 3–70 - NCT07565350Recruiting
Heat and hydrogen peroxide for stubborn viral warts
This trial tests combining local heat therapy with a hydrogen peroxide solution to treat viral warts that haven't responded to other treatments like freezing or lasers. The goal is to find a new option for people frustrated by warts that keep coming back.
Shenyang, LiaoningAges Any age - NCT07567274Enrolling by invitationPhase 2
DMSO Therapy for Ringing in Ears After COVID
This trial tests a combination therapy using DMSO (a chemical that penetrates tissues) mixed with several medications to treat persistent ringing in the ears (tinnitus) that developed or worsened after COVID-19 infection or vaccination. If you have bothersome tinnitus linked to long COVID or vaccine injury and haven't responded to previous treatments, this study may help.
Ithaca, New YorkAges 18–70 - NCT07559864RecruitingPhase 2
Regorafenib plus Envafolimab for treatment-resistant gastrointestinal stromal tumors
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06727721RecruitingPhase 2
Stem cell therapy for hard-to-treat type 2 diabetes
This trial tests a new stem cell treatment for people with type 2 diabetes that is difficult to control with standard medications. The treatment uses a special kind of stem cell to try to improve blood sugar levels.
ShanghaiAges 18–70 - NCT07556328Recruiting
Understanding Small-Bowel Disease Through Tissue Analysis
This research study examines tissue samples from your small bowel (the part of your digestive system after your stomach) to better understand celiac disease and related conditions. By studying these samples in detail, researchers hope to improve how doctors diagnose and treat small-bowel diseases.
TampereAges 18 years+
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,200 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.